Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

Intravenous Iron Supplementation in Korean Children on Chronic Dialysis

한국 만성 투석 소아 환자에서 정맥용 철분 제제 투여에 관한 연구

  • Cho, Hee-Yeon (Department of Pediatrics, Seoul National University Children's Hospital) ;
  • Hahn, Hye-Won (Department of Pediatrics, Eulji University School of Medicine) ;
  • Ha, Il-Soo (Department of Pediatrics, Eulji University School of Medicine) ;
  • Cheong, Hae-Il (Department of Pediatrics, Eulji University School of Medicine) ;
  • Choi, Yong (Department of Pediatrics, Eulji University School of Medicine)
  • 조희연 (서울대학교 어린이병원 소아청소년과) ;
  • 한혜원 (을지의대 소아과청소년과) ;
  • 하일수 (을지의대 소아과청소년과) ;
  • 정해일 (을지의대 소아과청소년과) ;
  • 최용 (을지의대 소아과청소년과)
  • Published : 2009.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : Limited information is available on experiences of intravenous iron treatment in children. In this study, iron sucrose was administered intravenously to determine its effect, the factors predicting outcome, and safety in children on chronic dialysis. Methods : Twenty-one children whose serum ferritin levels were less than 100 ng/mL or transferrin saturations (TSAT) were less than 20% were enrolled. In 12 children on peritoneal dialysis (PD), the drug was infused intravenously as 200 mg/$m^2$ ($\leq$200 mg) at week 0, 2, 4, and 6. In 9 children on hemodialysis (HD), it was given intravenously as 8 weekly doses of 3 mg/kg ($\leq$100 mg) through week 0-7. Results : After treatment, serum ferritin levels increased significantly in both groups, and TSAT rose significantly in PD group. However, hemoglobin level did not rise significantly in both groups. Children with baseline hemoglobin less than 10 g/dL or baseline TSAT less than 20% showed significantly higher rise of hemoglobin after intravenous iron treatment. To the contrary, those with higher baseline hemoglobin and TSAT levels displayed higher rise in serum ferritin after the treatment. Although no serious adverse event occurred, TSAT levels exceeding 50% were noted in 6 patients in PD group. Conclusion : This suggests that 3 mg/kg/week of intravenous iron sucrose can be used safely in children on chronic HD, but 200 mg/$m^2$ every other week may incur excessive TSAT level in some patients on chronic PD.

목적 : 소아에서 정맥용 철분 제제 투여에 대해서는 활용할 수 있는 연구 결과가 제한되어 있다. 이번 연구에서는 만성 투석 환아에게 정맥용 철분 수크로즈 제제를 투여함에 있어서 효과 및 결과 예측 인자, 안정성을 확인해 보고자 한다. 방법 : 혈청 페리틴 농도가 100 ng/mL 이하이거나 트랜스페린 포화도가 20% 이하인 21명의 만성 투석 환자가 선정되었다. 12명의 복막 투석 환자에게 철분 수크로즈를 체표면적당 200 mg의 용량으로 2주 간격으로 4회 투여하였고, 9명의 혈액 투석 환자에게 동일한 제제를 체중당 3 mg의 용량으로 일주일 간격으로 8회 투여하였다. 결과 : 치료 후 혈청 페리틴 농도는 양측 환자에서 유의한 상승을 보였고 복막 투석 환자에서는 트랜스페린 포화도가 유의한 상승을 보였다. 그러나 혈색소 수치는 양측 환자에서 모두 의미 있는 상승을 보이지는 않았다. 기저 혈색소 수치가 10 g/dL 이하이거나 기저 트랜스페린 포화도가 20% 이하인 환자는 정맥용 철분 제제 투여 후 의미있는 혈색소 상승을 보였다. 대조적으로 기저 혈색소 수치와 트랜스페린 포화도가 높았던 환자들은 치료 후 혈청 페리틴 수치의 상승을 보였다. 심각한 부작용은 없었으나 치료하는 과정에서 6명의 복막 투석 환자에서 50% 이상의 트랜스페린 포화도를 보였다. 결론 : 본 연구에서 혈액 투석 환아에서 일주일 간격으로 체중당 3 mg의 철분제제의 정맥 투여는 안전하게 사용될 수 있음을 확인할 수 있었던 반면, 복막 투석 환자에서 격주 간격으로 체표면적당 200 mg의 철분제제의 정맥 투여는 과도한 트랜스페린 포화도를 보일 수 있다.

Keywords

References

  1. KDOQI: National Kidney Foundation III. Clinical practice recommendations for anemia in chronic kidney disease in children. Am J Kidney Dis 2006;47(Suppl 3):S86-S108.
  2. Nissenson AR. Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life. Semin Nephrol 1989;9 (1 Suppl 2):25-31.
  3. Kausz AT, Obrador GT, Pereira BJ. Anemia management in patients with chronic renal insufficiency. Am J Kidney Dis 2000;36(Suppl 3):S39-51. https://doi.org/10.1053/ajkd.2000.19930
  4. Rigden SP, Montini G, Morris M, Clark KG, Haycock GB, Chantler C, Hill RC. Recombinant human erythropoietin therapy in children maintained by haemodialysis. Pediatr Nephrol 1990;4:618-22. https://doi.org/10.1007/BF00858637
  5. De Palo T, Giordano M, Palumbo F, Bellantuono R, Messina G, Colella V, Caringella AD. Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis. Pediatr Nephrol 2004;19:337-40. https://doi.org/10.1007/s00467-003-1364-1
  6. Warady BA, Sabath RJ, Smith CA, Alon U, Hellerstein S. Recombinant human erythropoietin therapy in pediatric patients receiving long-term peritoneal dialysis. Pediatr Nephrol 1991;5:718-23. https://doi.org/10.1007/BF00857883
  7. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989;35:134-48. https://doi.org/10.1038/ki.1989.18
  8. Muller-Wiefel DE, Sinn H, Gilli G, Scharer K. Hemolysis and blood loss in children with chronic renal failure. Clin Nephrol 1977;8:481-6.
  9. St Peter WL, Obrador GT, Roberts TL, Collins AJ. Trends in intravenous iron use among dialysis patients in the United States (1994-2002). Am J Kidney Dis 2005;46:650-60. https://doi.org/10.1053/j.ajkd.2005.06.018
  10. Warady BA, Zobrist RH, Wu J, Finan E; Ferrlecit Pediatric Study Group. Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol 2005;20:1320-7. https://doi.org/10.1007/s00467-005-1904-y
  11. Tenbrock K, Muller-Berghaus J, Michalk D, Querfeld U. Intravenous iron treatment of renal anemia in children on hemodialysis. Pediatr Nephrol 1999;13:580-2. https://doi.org/10.1007/s004670050747
  12. Gillespie RS, Wolf FM. Intravenous iron therapy in pediatric hemodialysis patients: a meta-analysis. Pediatr Nephrol 2004;19:662-6. https://doi.org/10.1007/s00467-004-1421-4
  13. Leijn E, Monnens LA, Cornelissen EA. Intravenous iron supplementation in children on hemodialysis. J Nephrol 2004;17:423-6.
  14. Morgan HE, Gautam M, Geary DF. Maintenance intravenous iron therapy in pediatric hemodialysis patients. Pediatr Nephrol 2001;16:779-83. https://doi.org/10.1007/s004670100645
  15. Van Damme-Lombaerts R, Herman J. Erythropoietin treatment in children with renal failure. Pediatr Nephrol 1999;13:148-52. https://doi.org/10.1007/s004670050584
  16. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-9. https://doi.org/10.1038/ki.1996.487
  17. Spinowitz BS, Schwenk MH, Jacobs PM, Bolton WK, Kaplan MR, Charytan C, Galler M. The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int 2005;68:1801-7. https://doi.org/10.1111/j.1523-1755.2005.00598.x
  18. Domrongkitchaiporn S, Jirakranont B, Atamasrikul K, Ungkanont A, Bunyaratvej A Indices of iron status in continuous ambulatory peritoneal dialysis patients, Am J Kidney Dis 1999;34:29-35. https://doi.org/10.1016/S0272-6386(99)70104-6
  19. Coyne D. Iron indices: what do they really mean- Kidney Int Suppl 2006;69:S4-8.
  20. Jones CH, Richardson D, Ayers S, Newstead CG, Will EJ, Davison AM, Percentage hypochromic red cells and the response to intravenous iron therapy in anaemic haemodialysis patients. Nephrol Dial Transplant 1998;13:2873-6. https://doi.org/10.1093/ndt/13.11.2873
  21. Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths ssociated with intravenous iron preparations, Nephrol Dial Transplant 2005;20:1443-9. https://doi.org/10.1093/ndt/gfh820
  22. Yorgin PD, Belson A, Sarwal M, Alexander SR. Sodium ferric gluconate therapy in renal transplant and renal failure patients. Pediatr Nephrol 2000;15:171-5. https://doi.org/10.1007/s004670000453
  23. Greenbaum LA, Pan CG, Caley C, Nelson T, Sheth KJ. Intravenous iron dextran and erythropoietin use in pediatric hemodialysis patients. Pediatr Nephrol 2000;14:908-11. https://doi.org/10.1007/s004670000326
  24. Warady BA, Kausz A, Lerner G, Brewer ED, Chadha V, Brugnara C, Dahl NV, Watkins SL. Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 2004;19:655-61. https://doi.org/10.1007/s00467-004-1457-5
  25. Richardson D, Bartlett C, Jolly H, Will EJ. Intravenous iron for CAPD populations: proactive or reactive strategies- Nephrol Dial Transplant 2001;16:115-9. https://doi.org/10.1093/ndt/16.1.115
  26. Harmeet Singh, John Reed, Sylvia Noble, Jose L. Cangiano, David B, Van Wyck. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. Clin J Am Soc Nephrol 2006;1:475-82. https://doi.org/10.2215/CJN.01541005
  27. Ahsan N. Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: a single center comparative study. J Am Soc Nephrol 1998;9:664-8.
  28. Anbu AT, Kemp T, O'donnell K, Smith PA, Bradbury MG. Low incidence of adverse events following 90-minute and 3-minute infusions of intravenous iron sucrose in children on erythropoietin. Acta Paediatr 2005;94:1738-41. https://doi.org/10.1080/08035250500281921
  29. Gokal R, Millard PR, Weatherall DJ, Callender STE, Ledingham JGG, Oliver DO. Iron metabolism in haemodialysis patients: A study of the management of iron therapy and overload. Q J Med 1979;48:369-91.
  30. Kletzmayr J, Horl WH. Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant 2002;17(Suppl 2):25-9.
  31. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3070-80. https://doi.org/10.1681/ASN.2005040423
  32. Weinberg ED. Iron withholding: A defense against infection and neoplasia. Physiol Rev 1984;64:65-102.
  33. Seifert A, Von Herrath D, Schaefer K. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. QJ Med 1987;65:1015-24.
  34. Hoen B, Kessler M, Hestin D, Fondu P, Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicenter prospective survey, Nephrol Dial Transplant 1995;10:377-81.
  35. Schaller G, Scheiber-Mojdehkar B, Wolzt M, Puttinger H, Mittermayer F, Horl WH, Fodinger M, Sunder-Plassmann G, Vychytil A. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients, Kidney Int 2005;68:2814-22. https://doi.org/10.1111/j.1523-1755.2005.00754.x
  36. Macdougall IC, Roche A. Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. Am J Kidney Dis 2005;46:283-9. https://doi.org/10.1053/j.ajkd.2005.04.032
  37. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001;38:988-91. https://doi.org/10.1053/ajkd.2001.28587